SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nicolien M van der Kolk, Sebastiaan Overeem, Nienke M de Vries, Roy PC Kessels, Rogier Donders, Marc Brouwer, Daniela Berg, Bart Post, Bas R Bloem, Design of the Park-in-Shape study: a phase II double blind randomized controlled trial evaluating the effects of exercise on motor and non-motor symptoms in Parkinson’s disease, BMC Neurology, 2015, 15, 1

    CrossRef

  2. 2
    Frederico Pieruccini-Faria, Kaylena A Ehgoetz Martens, Carolina RA Silveira, Jeffery A Jones, Quincy J Almeida, Interactions between cognitive and sensory load while planning and controlling complex gait adaptations in Parkinson’s disease, BMC Neurology, 2014, 14, 1

    CrossRef

  3. 3
    Yi Liu, Weina Li, Changhong Tan, Xi Liu, Xin Wang, Yuejiang Gui, Lu Qin, Fen Deng, Changlin Hu, Lifen Chen, Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease, Journal of Neurosurgery, 2014, 121, 3, 709

    CrossRef

  4. 4
    Stacey L. Gorniak, Andre G. Machado, Jay L. Alberts, Force coordination during bimanual task performance in Parkinson’s disease, Experimental Brain Research, 2013, 229, 2, 261

    CrossRef

  5. 5
    Robert M. Park, Neurobehavioral Deficits and Parkinsonism in Occupations with Manganese Exposure: A Review of Methodological Issues in the Epidemiological Literature, Safety and Health at Work, 2013, 4, 3, 123

    CrossRef

  6. 6
    Rosemarie M. Bowler, Matthew Harris, Vihra Gocheva, Katherine Wilson, Yangho Kim, Stephanie I. Davis, George Bollweg, Danelle T. Lobdell, Long Ngo, Harry A. Roels, Anxiety affecting parkinsonian outcome and motor efficiency in adults of an Ohio community with environmental airborne manganese exposure, International Journal of Hygiene and Environmental Health, 2012, 215, 3, 393

    CrossRef

  7. 7
    H.A. Roels, R.M. Bowler, Y. Kim, B. Claus Henn, D. Mergler, P. Hoet, V.V. Gocheva, D.C. Bellinger, R.O. Wright, M.G. Harris, Y. Chang, M.F. Bouchard, H. Riojas-Rodriguez, J.A. Menezes-Filho, Martha Maria Téllez-Rojo, Manganese exposure and cognitive deficits: A growing concern for manganese neurotoxicity, NeuroToxicology, 2012, 33, 4, 872

    CrossRef

  8. 8
    Cindy M. de Frias, Roger A. Dixon, Richard Camicioli, Neurocognitive Speed and Inconsistency in Parkinson's Disease with and without Incipient Dementia: An 18-Month Prospective Cohort Study, Journal of the International Neuropsychological Society, 2012, 18, 04, 764

    CrossRef

  9. 9
    Sydney E. Seidel, Barbara C. Tilley, Peng Huang, Yuko Y. Palesch, Kenneth J. Bergmann, Christopher G. Goetz, Christopher J. Swearingen, Subject-investigator reproducibility of the Unified Parkinson’s Disease Rating Scale, Parkinsonism & Related Disorders, 2012, 18, 3, 230

    CrossRef

  10. 10
    C.G. Goetz, Encyclopedia of Movement Disorders, 2010,

    CrossRef

  11. 11
    Cristina Sampaio, Can focusing on UPDRS Part II make assessments of Parkinson disease progression more efficient?, Nature Clinical Practice Neurology, 2009, 5, 3, 130

    CrossRef

  12. 12
    Thomas Müller, Kira Kolf, Lema Ander, Dirk Woitalla, Siegfried Muhlack, Catechol-O-methyltransferase Inhibition Improves Levodopa-Associated Strength Increase in Patients With Parkinson Disease, Clinical Neuropharmacology, 2008, 31, 3, 134

    CrossRef

  13. 13
    Karla M Eggert, Jens P Reese, Wolfgang H Oertel, Richard Dodel, Cost Effectiveness of Pharmacotherapies in Early Parkinson’s Disease, CNS Drugs, 2008, 22, 10, 841

    CrossRef

  14. You have free access to this content14
    Birgit Meiler, Jürgen Andrich, Thomas Müller, Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion, Movement Disorders, 2008, 23, 1
  15. 15
    T. Müller, L. Ander, K. Kolf, D. Woitalla, S. Muhlack, Comparison of 200 mg retarded release levodopa/carbidopa – with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson’s disease, Journal of Neural Transmission, 2007, 114, 11, 1457

    CrossRef

  16. 16
    Thomas Müller, Christoph Erdmann, Siegfried Muhlack, Dirk Bremen, Horst Przuntek, Dirk Woitalla, Entacapone improves complex movement performance in patients with Parkinson’s disease, Journal of Clinical Neuroscience, 2007, 14, 5, 424

    CrossRef

  17. You have free access to this content17
    Christopher G. Goetz, Stanley Fahn, Pablo Martinez-Martin, Werner Poewe, Cristina Sampaio, Glenn T. Stebbins, Matthew B. Stern, Barbara C. Tilley, Richard Dodel, Bruno Dubois, Robert Holloway, Joseph Jankovic, Jaime Kulisevsky, Anthony E. Lang, Andrew Lees, Sue Leurgans, Peter A. LeWitt, David Nyenhuis, C. Warren Olanow, Olivier Rascol, Anette Schrag, Jeanne A. Teresi, Jacobus J. Van Hilten, Nancy LaPelle, Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan, Movement Disorders, 2007, 22, 1
  18. 18
    Rosemarie M. Bowler, Sanae Nakagawa, Marija Drezgic, Harry A. Roels, Robert M. Park, Emily Diamond, Donna Mergler, Maryse Bouchard, Russell P. Bowler, William Koller, Sequelae of fume exposure in confined space welding: A neurological and neuropsychological case series, NeuroToxicology, 2007, 28, 2, 298

    CrossRef

  19. 19
    Pablo Martínez-Martín, Esther Cubo, Parkinson's Disease and Related Disorders, Part I, 2007,

    CrossRef

  20. 20
    T. Müller, C. Erdmann, S. Muhlack, D. Bremen, H. Przuntek, O. Goetze, D. Woitalla, Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease, Journal of Neural Transmission, 2006, 113, 10, 1441

    CrossRef

  21. 21
    C Warren Olanow, Anthony HV Schapira, Peter A LeWitt, Karl Kieburtz, Dirk Sauer, Gianfranco Olivieri, Harald Pohlmann, Jean Hubble, TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial, The Lancet Neurology, 2006, 5, 12, 1013

    CrossRef

  22. 22
    Joel S. Perlmutter, Assessment of Parkinson Disease Manifestations, Current Protocols in Neuroscience,